20 results about "Lysyl oxidase" patented technology

The current disclosure is centered on the hypothesis that a better understanding of the neuroendocrine transdifferentiation (NEtD) process will provide therapeutic targets for inhibiting this transition and thus improving standard of care therapies. Accordingly, the current disclosure provides for a method for treating cancer in a subject, the method comprising administering an inhibitor of a gene, wherein the gene comprises one or more of tenascin C (TNC), advillin (AVIL), S100A7, PPARG, LOX lysyl oxidase, KLF5, APOBEC2, FOSL1, FOXM1, hedgehog, RELA, p65, IKK complex, JAK, STAT, TFAP4, geminin, OCA-1, OCA-2, Nf-kB, Nf-kB family and associated regulators, angiogenesis regulators such as BMX kinase, TEK kinase, periostin (POSTN), and VEGF family, stress genes, such as the JUN / FOS family, a gene from the S100 family, and cell state regulators such as ASCL1, POU2F3, NEUROD1, ASCL2, and YAP1.

The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and / or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.

An isolated peptide comprising an amino acid sequence of a lysyl oxidase (LOX) family member target site of an extracellular matrix protein, the peptide being no longer than 50 amino acids, for use in treating a disease associated with fibrosis in a subject in need thereof.

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The invention discloses a golden triangular support anti-aging method. The method comprises the following steps: S1, barrier pretreatment; S2, active component delivery; S3, photocuring network shaping; according to the golden triangle support anti-aging method, synthesis and degradation balance of three core components of a skin extracellular matrix are synergistically regulated and controlled, and a golden triangle support system is formed. The small molecule peptide Pro-Hyp-Gly in the collagen activation component and the copper ion chelate act together, so that fibroblasts are promoted to secrete collagen, and the skin supporting force is enhanced; beta-aminopropionitrile serving as a lysyl oxidase inhibitor in the elastin protection component and vitamin E succinate have a synergistic effect, so that the degradation of elastin is inhibited, and the skin elasticity is maintained; the hyaluronic acid synergistic component is compounded by hyaluronic acid with different molecular weights to form a graded water locking network, so that the water content and plumpness of the skin are improved.

To provide frozen noodles causing little evaporation of water from the noodles after boiled while improving the production efficiency of the frozen noodles, having firm texture to such an extent that the core does not remain when eaten, and having smooth texture on the surface.SOLUTION: It has been found that when a lysyl oxidase derived from an eggshell membrane is used, noodles having no remaining core and having firm texture are obtained even after a short boiling time, the noodles hardly spread even after a prolonged boiling time, and the surface of the noodles after washing with water is smooth without unevenness and excellent in slipperiness.SELECTED DRAWING: None

Sunscreen compositions and sunscreen active ingredients are disclosed herein which comprise at least one ketone-containing UV filter and at least one primary or secondary amine wherein at least one ketone-containing UV filter and at least one primary or secondary amine react to form an imine analog of the ketone-containing UV filter wherein the imine analog has at least one property selected from the group consisting of a) is capable of extending UV protection into a visible region equal to or greater than 400 nm, b) is water resistant, and / or c) prevents or decreases skin penetration. This imine analog may be further modified to provide a substrate capable of reacting with transglutaminase or any variant thereof and / or a lysyl oxidase to bind the sunscreen composition or sunscreen active ingredient to a target of interest. Also disclosed are cosmetic or pharmaceutical preparations comprising any of the sunscreen compositions or sunscreen ingredients along with a cosmetically or pharmaceutically acceptable carrier.

According to the method for fermenting the traditional rare Chinese herbal medicine in the duplex tank reactor through the saccharomycetes, fermentation is conducted through the Saccharomyces cerevisiae YALAN1, the content of effective substances in a fermentation product is increased, and it is guaranteed that the fermentation product has certain oxidation resistance and tyrosinase inhibitory activity; and the fermentation process is carried out in the duplex tank reactor, so that the small-scale test fermentation level in a laboratory is successfully improved to the pilot-scale test fermentation level (5L * 2), and the method has guiding significance for industrial application. In the whole fermentation process, only a solvent'water 'is introduced, and almost no refining and impurity removing procedure is performed subsequently, so that risk substances such as ethanol and trichloromethane are not introduced while the economical efficiency is ensured, and the method is environment-friendly and safe.

Provided are a bicyclic fused ring such as for example, benzo[d]imidazole, benzo[d][1,2,3]triazole, or 8-oxo-8,9-dihydro-7H-purine derivatives or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the bicyclic fused ring derivative or pharmaceutically acceptable salt thereof has an inhibitory activity against the lysyl oxidase family and can be usefully applied for preventing or treating various diseases associated with the lysyl oxidase family, such as idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), or liver cirrhosis.

The invention provides gradient bio-ink of a three-dimensional bionic corneal stroma scaffold and a 3D printing preparation process. The gradient bio-ink comprises 5-30 parts of a natural polymer matrix, 2-8 parts of a bioactive factor, 1-5 parts of a cell component, 1-10 parts of a light curing agent and 60-95 parts of normal saline. The natural polymer matrix contains methylacryloylated gelatin, a collagen / hyaluronic acid protein compound and chitosan, and the collagen / hyaluronic acid protein compound is prepared through lysyl oxidase cross-linking and visible light photocuring. After the bio-ink is prepared, an extrusion type 3D printer is adopted for printing layer by layer under specific conditions, ultraviolet irradiation is synchronously performed, and the three-dimensional bionic corneal stroma scaffold is prepared. The scaffold disclosed by the invention has good mechanical properties, light transmission and cell compatibility, can support directional differentiation of stem cells, and is suitable for cornea repair.

In general, disclosed herein are lysyl oxidase (LOX) family inhibitors of Formula (A): or a pharmaceutically acceptable salt thereof. Additionally, disclosed herein are methods directed to treating a disease of condition associated with the modulation or inhibition of lysyl oxidase (LOX).

The present invention relates to novel bioprobes which are capable of binding to certain amine oxidase enzymes. These bioprobes are useful in methods of detecting and determining the concentration of certain amine oxidase enzymes in a sample as well as in methods for the quantitative assessment of inhibition of certain amine oxidases.

A method for treating fibrosis in a subject in need thereof is provided. The method comprises administering to the subject a polypeptide comprising a propeptide of lysyl oxidase (LOX), the polypeptide lacking LOX catalytic activity, thereby treating fibrosis in the subject, wherein the method does not include administration of D-penicillamine. A polypeptide composition for use in therapy is also provided.

A method of treating a cancer which is characterized by an up-regulation of expression of lysyl oxidase (LOX) and heat shock protein 70 (HSP70) is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a propeptide of lysyl oxidase (LOX), said polypeptide being devoid of LOX catalytic activity, wherein said polypeptide binds to both LOX and heat shock protein 70 (HSP70) with a EC50 of less than 100 nM.

Compositions and methods for cosmetic applications are disclosed. The composition can contain ascorbic acid tetrahexyldecanol ester, phyllanthus emblica fruit extract, tocopherol and ascorbic acid. The composition may also comprise a plant amino acid. An effective amount of the composition may be applied to the skin to stimulate collagen production and lysyl oxidase activity, inhibit tyrosinase, inhibit melanogenesis and / or COX-1 activity, and inhibit matrix metalloproteinase activity in the skin.

The application belongs to the field of medicine and biology, and relates to an anti-pan-lysyl oxidase family nanobody or antigen binding fragment and application. The anti-pan-lysyl oxidase family nanobody or antigen binding fragment comprises three complementarity determining regions CDR1, CDR2 and CDR3; wherein the amino acid sequence of CDR1 is a sequence shown in one of SEQ ID NO:1 to SEQ ID NO:8, the amino acid sequence of CDR2 is a sequence shown in one of SEQ ID NO:9 to SEQ ID NO:17, and the amino acid sequence of CDR3 is a sequence shown in one of SEQ ID NO:18 to SEQ ID NO:26. The application uses a flow washing method to screen a library, and finally obtains an anti-human / mouse anti-pan-lysyl oxidase family nanobody gene sequence. The anti-pan-lysyl oxidase family nanobody of the application has small molecular weight, high affinity and good specificity. The anti-pan-lysyl oxidase family nanobody has good prospects for development as a diagnostic fibrosis.

Lysyl oxidase (LOX) inhibitors, lysyl oxidase-like (LOXL) inhibitors, or pharmaceutically acceptable salts thereof and methods for the treatment of myeloid malignancies, comprising administering a therapeutically effective amount of those inhibitors alone or optionally in combination with a second therapeutic agent.

Methods are disclosed for treating a subject with a disorder, such as, but not limited to, a) fibrosis of an organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63loCD81lo. In additional embodiments, methods are disclosed for increasing myoblast differentiation.

The invention discloses biological crosslinking and chemical crosslinking combined collagen and a preparation method thereof, and belongs to the technical field of medical hydrogel materials, the collagen is recombinant I-type collagen, and is obtained by fully mixing the recombinant I-type collagen with EDC / NHS, then adding lysyl oxidase and retreating, and the biological crosslinking and chemical crosslinking combined collagen is prepared. And swelling the recombinant type I collagen in normal saline to obtain the recombinant type I collagen hydrogel. The collagen and the recombinant I-type collagen hydrogel have the advantages of being low in cytotoxicity, excellent in cytocompatibility, not prone to causing collagen denaturation and the like.